1083
document
Low-dose growth hormone treatment with diet restriction accelerates body fat loss , exerts anabolic effect and improves growth hormone secretory dysfunction in obese adults . Growth hormone ( GH ) can induce an accelerated lipolysis . Impaired secretion of GH in obesity results in the consequent loss of the lipolytic effect of GH . Dietary restriction as a basic treatment for obesity is complicated by poor compliance , protein catabolism , and slow rates or weight loss . GH has an anabolic effect by increasing insulin-like growth factor ( IGF ) -I . We investigated the effects of GH treatment and dietary restriction on lipolytic and anabolic actions , as well as the consequent changes in insulin and GH secretion in obesity . 24 obese subjects ( 22 women and 2 men ; 22-46 years old ) were fed a diet of 25 kcal/kg ideal body weight ( IBW ) with 1.2 g protein/kg IBW daily and were treated with recombinant human GH ( n = 12 , 0.18 U/kg IBW/week ) or placebo ( n = 12 , vehicle injection ) in a 12-week randomized , double-blind and placebo-controlled trial . GH treatment caused a 1.6-fold increase in the fraction of body weight lost as fat and a greater loss of visceral fat area than placebo treatment ( 35.3 vs. 28.5 % , p < 0.05 ) . In the placebo group , there was a loss in lean body mass ( -2.62 +/- 1.51 kg ) and a negative nitrogen balance ( -4.52 +/- 3.51 g/day ) . By contrast , the GH group increased in lean body mass ( 1.13 +/- 1.04 kg ) and had a positive nitrogen balance ( 1.81 +/- 2.06 g/day ) . GH injections caused a 1.6-fold increase in IGF-I , despite caloric restriction . GH response to L-dopa stimulation was blunted in all subjects and it was increased after treatment in both groups . GH treatment did not induce a further increase in insulin levels during an oral glucose tolerance test ( OGTT ) but significantly decreased free fatty acid ( FFA ) levels during OGTT . The decrease in FFA area under the curve during OGTT was positively correlated with visceral fat loss . This study demonstrates that in obese subjects given a hypocaloric diet , GH accelerates body fat loss , exerts anabolic effects and improves GH secretion . These findings suggest a possible therapeutic role of low-dose GH with caloric restriction for obesity .
1084
Intervention_Pharmacological
Low-dose growth hormone treatment with diet restriction
1085
Intervention_Pharmacological
Growth hormone
1086
Intervention_Pharmacological
diet
1087
Intervention_Pharmacological
recombinant human GH
1088
Intervention_Control
placebo
1089
Intervention_Pharmacological
GH
1090
Intervention_Pharmacological
GH
1091
Intervention_Pharmacological
GH injections
1092
Intervention_Pharmacological
GH
1093
Intervention_Pharmacological
GH
1094
Outcome_Physical
accelerates body fat loss , exerts anabolic effect and improves growth hormone secretory dysfunction
1095
Outcome_Physical
accelerated lipolysis
1096
Outcome_Physical
lipolytic effect of GH
1097
Outcome_Physical
insulin-like growth factor ( IGF ) -I
1098
Outcome_Physical
lipolytic and anabolic actions
1099
Outcome_Physical
insulin
1100
Outcome_Physical
GH secretion
1101
Outcome_Physical
fraction of body weight lost as fat and a greater loss of visceral fat area
1102
Outcome_Physical
lean body mass
1103
Outcome_Physical
negative nitrogen balance
1104
Outcome_Physical
lean body mass
1105
Outcome_Physical
positive nitrogen balance
1106
Outcome_Physical
increase in IGF-I
1107
Outcome_Physical
GH response to L-dopa stimulation
1108
Outcome_Physical
insulin levels
1109
Outcome_Physical
free fatty acid ( FFA ) levels
1110
Outcome_Physical
FFA area
1111
Outcome_Physical
visceral fat loss
1112
Outcome_Physical
body fat loss
1113
Outcome_Physical
exerts anabolic effects
1114
Outcome_Physical
GH secretion
1115
Participant_Condition
obese
1116
Participant_Age
adults
1117
Participant_Condition
obesity
1118
Participant_Sample-size
24
1119
Participant_Condition
obese
1120
Participant_Sample-size
22
1121
Participant_Sex
women
1122
Participant_Sample-size
2
1123
Participant_Sex
men
1124
Participant_Age
22-46 years
1125
Participant_Condition
obese